ISPAD 2024 Guidelines: New Glycemic Targets and Tech in Pediatric Diabetes
The 2024 ISPAD Clinical Practice Consensus Guidelines represent a pivotal update in pediatric diabetes care, celebrating 50 years of the organization. This 7th edition introduces six high-impact chapters focused on technology, screening, and treatment . A landmark change is the new, lower HbA1c target of ≤6.5% (48 mmol/mol) for children using advanced technologies like CGM and AID systems . The guidelines also feature a more rigorous evidence-based methodology and emphasize the importance of early CGM use and FDA-approved therapies like teplizumab
The landscape of pediatric and adolescent diabetes care is constantly evolving, driven by technological breakthroughs, novel therapies, and a deeper understanding of the disease's pathophysiology. For healthcare professionals dedicated to improving the lives of young people with diabetes, staying current with the latest evidence-based recommendations is not just beneficial—it is essential.
In 2024, the International Society for Pediatric and Adolescent Diabetes (ISPAD) released its latest Clinical Practice Consensus Guidelines (CPCG). These guidelines serve as the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes globally . The 2024 edition marks the 7th iteration of this seminal document, building upon the foundations laid in 1995,…
Reviewed by the LibraryMedicine.com Clinical Editorial Board. Our authors are practicing physicians and medical educators dedicated to delivering evidence-based, up-to-date clinical guides.
Comments (0)